|
|
|
|
|
|||||||
|
Session 73
Poster Session
Adherence to Therapy 4:30-6:30 pm 4E-F |
to view the poster for an abstract.| 540-T. | Randomized Study of Telephone Calls to Improve Adherence to Antiretroviral Therapy A. C. Collier *1, H. Ribaudo2, J. Feinberg3, L. Mukherjee2, M. Fischl4, and M. Chesney5 for the ACTG Protocol 746 Team 1Univ. of Washington, Seattle; 2Harvard Sch. of Publ. Hlth., Boston, MA; 3Univ. of Cincinnati, OH; 4Univ. of Miami, FL; and 5Univ. of California, San Francisco
| ||
| 541-T. | Counseling Interventions Can Improve Adherence to Highly Active Antiretroviral Therapy: Results of a French Prospective Controlled Study C. Pradier*1, 2, L. Bentz2, B. Spire1, C. Tourette-Turgis3, M. Morin1, J. G. Fuzibet2, A. Pesce2, P. Dellamonica1, 2, J. P. Moatti1, and 4 1INSERM U379, Marseilles; 2CISIH, L’Archet Hosp., Nice; 3Univ. of Rouen; and 4Univ. of the Mediterranean, Marseilles, France
| ||
| 542-T. | Mock Antiretroviral Therapy Trials as an Assessment Tool for Adherence: Correlates with Subsequent HIV Suppression R. Lubelchek*, C. Gabler, G. Berry, N. Wiederhold, J. Cacciabando, G. Highstein, and L. Mundy Washington Univ. Sch. of Med., St. Louis, MO
| ||
| 543-T. | Predictors of Adherence and Efficacy in HIV-1-Infected Patients Treated with Abacavir/Combivir (ABC/COM) or Indinavir/Combivir (IDV/COM): Final 48-Week Data from CNA3014 J. Jordan*1, P. Cahn2, and A. Vibhagool3 for the CNA3014 Study Team 1GlaxoSmithKline, Res. Triangle Park, NC; 2Fndn. HUESPED, Buenos Aires, Argentina; and 3Ramathibodi Hosp., Mahidol Univ., Bangkok, Thailand
| ||
| 544-T. | Predictive Value of Electronic Monitoring of HAART Adherence in Patients with Acute and Early HIV Infection M. Sanchez1, B. Sabundayo*1, S. Langan1, A. Lindsay1, C. Flexner2, and J. Margolick1 1Johns Hopkins Univ. Sch. of Publ. Hlth. and 2Johns Hopkins Univ. Sch. of Med., Baltimore, MD
| ||
| 545-T. | Nevirapine (NVP) and Protease Inhibitor (PI)-Based Regimens in a Directly Observed Therapy (DOT) Program for Intravenous Drug Users (IDUs) B. Conway*1, J. Prasad1, R. Reynolds1, J. Farley1, N. Smith2, A. Meade2, and S. Devlaming2 1Univ. of British Columbia and 2St-Paul's Hosp., Vancouver, BC, Canada
| ||
| 546-T. | Low Levels of Adherence Do Not Increase Risk of HIV Drug Resistance Mutations D. R. Bangsberg*1, E. D. Charlebois1, R. M. Grant2, M. Holodniy3, S. Perry1, K. Nugent Conroy4, D. Guzman1, A. Zolopa4, and A. R. Moss1 1San Francisco Gen. Hosp., CA; 2Gladstone Inst. of Virlogy, San Francisco, CA; 3Palo Alto VA Med. Ctr., CA; and 4Stanford Univ., Palo Alto, CA
| ||
| 547-T. | Longitudinal Assessment of the Effects of Drug and Alcohol Abuse on HIV Treatment G. Lucas*, K. Gebo, R. E. Chaisson, and R. Moore Johns Hopkins Univ. Sch. of Med., Baltimore, MD
|
